Our investments

Labo Smeets continues to invest in people, hardware and software.

The credo of our investment policy is aimed at quality and reliability of our pharmaceutical powder packaging activity.

People

We ensure continuous education for our staff and take good care about our people. We have a very low turnover rate, while remaining dedicated to continuously improve productivity, service levels and quality.

Hardware

Our investment in equipment ranges from state of the art production units for blending, to laminar air flow protected filling. All production lines operate through separate double rooms.

Investing for customers

In some cases we have developed processes tailored towards the needs of our customers. This resulted in long term agreements where Labo Smeets has done the investment for the customer

The most succesfull cases are those where we are involved early in the lifecycle of a newly developed product set.

Our investments Our investments Our investments

LABORATORIA SMEETS N.V.

Fotografielaan 42
B-2610 Antwerpen-Wilrijk
Tel. +32 (0)3 828 29 37
Fax +32 (0)3 830 21 36
e-mail: info@labosmeets.be

EN  NL  FR  DE  ES 
CASE:  

Read more...

Read more...
CASE: New Technology for API solubility  

In collaboration with the University of Ghent, Labo Smeets has realised a new process in pharmaceutical extrusion technology, which enables us to make highly soluble granules. The main application is to make pharmaceutical granule compositions to drastically improve water solubility of active ingredients. The technology is applicable for the following drug ...
Read more...
New Technology for API solubility

In collaboration with the University of Ghent, Labo Smeets has realised a new process in pharmaceutical extrusion technology, which enables us to make granules. The main application is to make pharmaceutical granule compositions to drastically improve water solubility of active ingredients. This equipment is installed and available since January 2011.

Read more...
CASE: Product innovation  

A customer identified a patented technology at one of the Belgian universities to make one of their products easier to administer. We were contacted at an early stage to help with developing the product. We jointly decided to set up a test manufacturing unit in order to produce small batches for the clinical trials. As the project outcome was uncertain, ...
Read more...
CASE: Speed to market  

A customer found an opportunity to launch an anti-allergic product in one of its markets. The opportunity came up quickly, but the product design wasn’t ready, nor were the sales forecasts. The marketing team instructed to identify the swiftest supplier to realize the product launch. In less than 2 weeks, we were able to present a fully elaborated ...
Read more...
CASE: Strategic procurement  

One of  our pharmacuetical customers is a large consumer of raw materials. Often large pharmaceutical customers are constrained with their raw materials procurement strategies. The complexity of the regulatory filing for many of their products, prevents them from obtaining the best deal. Underlying causes are the intrinsic speed of action, but also the ...
Read more...